Eribulin Mesylate

Base Information

• Chemical Name: Eribulin Mesylate
• CAS No.: 441045-17-6
• Molecular Formula: C40H59NO11.CH4O3S
• Molecular Weight: 826.00200
• European Community (EC) Number: 813-106-4
• UNII: AV9U0660CW
• ChEMBL ID: CHEMBL1683544
• NCI Thesaurus Code: C26644
• RXCUI: 1045452
• Wikidata: Q27882076
• Mol file: 441045-17-6.mol

Synonyms:2-(3-amino-2-hydroxypropyl)hexacosahydro-3-methoxy-26-methyl-20,27-bis(methylene)11,15-18,21-24,28-triepoxy-7,9-ethano-12,15-methano-9H,15H-furo(3,2-i)furo(2',3'-5,6)pyrano(4,3-b)(1,4)dioxacyclopentacosin-5-(4H)-one;B 1793;B 1939;B-1793;B-1939;E 7389;E-7389;ER 086526;ER-086526;ER-86526;ER086526;eribulin;eribulin (as mesylate);eribulin mesilate;eribulin mesylate;eribulin monomethanesulfonate;Halaven;NSC 707389;NSC-707389;NSC707389

Chemical Property of Eribulin Mesylate

Chemical Property:

• PSA: 209.14000
• LogP: 4.72310
• Solubility.: Soluble in DMSO
• Hydrogen Bond Donor Count: 3
• Hydrogen Bond Acceptor Count: 15
• Rotatable Bond Count: 4
• Exact Mass: 825.39692686
• Heavy Atom Count: 57
• Complexity: 1470

Purity/Quality:

99%, ^*data from raw suppliers

Eribulin(mesylate) 99.52% ^*data from reagent suppliers

Safty Information:

• Pictogram(s):  
• Hazard Codes: 

MSDS Files:

SDS file from LookChem

Useful:

• Canonical SMILES: CC1CC2CCC3C(=C)CC(O3)CCC45CC6C(O4)C7C(O6)C(O5)C8C(O7)CCC(O8)CC(=O)CC9C(CC(C1=C)O2)OC(C9OC)CC(CN)O.CS(=O)(=O)O
• Isomeric SMILES: C[C@@H]1C[C@@H]2CC[C@H]3C(=C)C[C@@H](O3)CC[C@]45C[C@@H]6[C@H](O4)[C@H]7[C@@H](O6)[C@@H](O5)[C@@H]8[C@@H](O7)CC[C@@H](O8)CC(=O)C[C@H]9[C@H](C[C@H](C1=C)O2)O[C@@H]([C@@H]9OC)C[C@@H](CN)O.CS(=O)(=O)O
• Recent ClinicalTrials: Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer
• Recent EU Clinical Trials: PHASE II STUDY FOR PIK3CA/PTEN-ALTERED ADVANCED METAPLASTIC BREAST CANCER TREATED WITH MEN1611 MONOTHERAPY OR IN COMBINATION WITH ERIBULIN -THE SABINA STUDY-
• Recent NIPH Clinical Trials: A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy
• Uses: Eribulin Mesylate is a synthetic analog of the marine natural product halichondrin B.
• Clinical Use: Eribulin is a highly potent cytotoxic agent approved in the U.S. for the treatment of metastatic breast cancer for patients who have received at least two previous chemotherapeutic regimens. Eribulin was discovered and developed by Eisai and it is currently undergoing clinical evaluation for the treatment of sarcoma (PhIII) and non-small cell lung cancer which shows progression after platinumbased chemotherapy and for the treatment of prostate cancer (PhII). Early stage clinical trials are also underway to evaluate eribulin’s efficacy against a number of additional cancers. Eribulin is a structural analog of the marine natural product halichondrin B. Its mechanism of action involves the disruption of mitotic spindle formation and inhibition of tubulin polymerization which results in the induction of cell cycle blockade in the G2/M phase and apoptosis. Eribulin mesylate, a nontaxane, completely synthetic microtubule inhibitor, has recently been approved by the U.S. Food and Drug Administration as third-line treatment of metastatic breast cancer refractory to anthracyclines and taxanes.